Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.7554/eLife.55570 http://scihub22266oqcxt.onion/10.7554/eLife.55570 32091395!7060038!32091395     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Elife 2020 ; 9 (ä): ä Nephropedia Template TP {{tp|p=32091395|t=2020. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19 |pdf=|usr=}}{{32091395}} gab.com Text Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19 JO: Elife http://www.kidney.de/pget.php?&tw=1&pmid=32091395 #FOAvip Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens. Twit Text FOAVip Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19 ????Elife http://www.kidney.de/pget.php?&tw=1&pmid=32091395 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32091395 #FOAvip English Wikipedia <ref>{{Cite pmid|32091395}}</ref> Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19 #MMPMID32091395 Gostic K; Gomez AC; Mummah RO; Kucharski AJ; Lloyd-Smith JO Elife 2020[Feb]; 9 (ä): ä PMID32091395show ga Traveller screening is being used to limit further spread of COVID-19 following its recent emergence, and symptom screening has become a ubiquitous tool in the global response. Previously, we developed a mathematical model to understand factors governing the effectiveness of traveller screening to prevent spread of emerging pathogens (Gostic et al., 2015). Here, we estimate the impact of different screening programs given current knowledge of key COVID-19 life history and epidemiological parameters. Even under best-case assumptions, we estimate that screening will miss more than half of infected people. Breaking down the factors leading to screening successes and failures, we find that most cases missed by screening are fundamentally undetectable, because they have not yet developed symptoms and are unaware they were exposed. Our work underscores the need for measures to limit transmission by individuals who become ill after being missed by a screening program. These findings can support evidence-based policy to combat the spread of COVID-19, and prospective planning to mitigate future emerging pathogens. |*Asymptomatic Infections[MESH] |*Betacoronavirus/isolation & purification[MESH] |*Mass Screening/methods/standards[MESH] |*Travel[MESH] |COVID-19[MESH] |Coronavirus Infections/*diagnosis/epidemiology/transmission[MESH] |Disease Outbreaks[MESH] |Humans[MESH] |Infection Control[MESH] |Pneumonia, Viral/*diagnosis/epidemiology/transmission[MESH] |Risk Assessment[MESH]Estimated effectiveness of symptom and risk screening to prevent the s(epmc).pdf DeepDyve Pubget Overpricing